Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03622307
Other study ID # VT ablation/SICD study
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2018
Est. completion date October 1, 2019

Study information

Verified date August 2018
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients. This is a single arm prospective study with 30 patients eligible for implantation of an ICD for the secondary prevention of sudden cardiac death.


Description:

The subcutaneous ICD (S-ICD) is a system without transvenous leads that has been proven to safely provide defibrillation for patients at risk of sudden cardiac death due to ventricular tachyarrhythmias. However this system is currently not able to perform anti tachycardia pacing (ATP) which can terminate some VT, thus avoiding painful shocks.

Ideally slow VT should be managed with RF ablation while fast VT causing hemodynamic consequences should be treated with ICD shocks combined with medications. Typically, ICDs in secondary prevention patients are programmed to intervene at 10 msec at least above the clinical VT. In cases of hemodynamically stable VT this can result in unnecessary therapies and lead to ICD shocks. S-ICD can safely manage fast VTs while slower hemodynamically VTs can be managed with ablation.

This approach can avoid transvenous ICD related complications and unnecessary ICD interventions such as ATP which can accelerate VT to ICD shock zone. However, the benefit of this management strategy compared to conventional transvenous ICD programming has not been studied in patients who receive the device for the secondary prevention of sudden cardiac death.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date October 1, 2019
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria:

- Any scar related sustained VT or VF

- Class I, IIa, or IIb indication for secondary prevention ICD therapy per ESC Guidelines

- Age = 22 years on a date of consent

- LVEF = 40%

- Positive ECG screening for S-ICD

Exclusion Criteria:

- A requirement for antibradycardia pacing or CRTD

- Subjects with an existing ICD, CRT, CRT-D, or pacemaker device.

- Contraindications for S-ICD implantation

- Contraindications for VT ablation

- Serious known concomitant disease with a life expectancy of < 1 year

- Elderly patients >80 years of age

- NYHA class IV or need for mechanical LV support (ECMO)

- Pregnancy or nursing

- Unwilling or unable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Subcutaneous ICD Therapy Combined with VT Ablation
S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Outcome

Type Measure Description Time frame Safety issue
Other All cause mortality Rate of all cause mortality. This will be assessed during patient follow up. 24 months
Other Cardiac mortality Rate of all cardiac mortality. This will be assessed during patient follow up. 24 months
Primary arrhythmic event Occurrence of treated arrhythmic event (appropriate and inappropriate). The primary endpoint will be assessed by patient interview, clinical examination, and regularly scheduled SICD interrogation during follow-up 24 months
Secondary Appropriate ICD therapy Rate of appropriate ICD therapy (defined as a shock therapy for ventricular tachycardia or fibrillation).
This will be assessed by patient interview and regularly scheduled ICD interrogation during follow-up.
24 months
Secondary Inappropriate ICD therapy Rate of inappropriate therapy (defined as any ICD shock delivered for Non-VT event).
This will be assessed by patient interview and regularly scheduled ICD interrogation during follow-up.
24 months
Secondary Ablation success rates Rate of ablation success (defined as absence of Ventricular Arrhythmia). This will be assessed by patient interview and regularly scheduled ICD interrogation during follow-up. 24 months
See also
  Status Clinical Trial Phase
Completed NCT02923726 - Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP N/A
Recruiting NCT05175937 - REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
Completed NCT02026102 - A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs) N/A
Completed NCT01262508 - Development of Algorithms to Predict Hemodynamic Instability N/A
Completed NCT00998218 - Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction Phase 3
Completed NCT00845286 - Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial N/A
Active, not recruiting NCT00562757 - Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias N/A
Completed NCT00622453 - Arrhythmias in Myotonic Muscular Dystrophy N/A
Completed NCT03833843 - Sudden Cardiac Death in Systemic Right Ventricle
Completed NCT04024865 - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Recruiting NCT05799833 - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting NCT05694572 - Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
Recruiting NCT02056509 - The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation. N/A
Recruiting NCT02058771 - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Terminated NCT01948206 - Study of Paced QRS Duration as a Marker of Sudden Cardiac Death N/A
Completed NCT01227785 - Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study N/A
Completed NCT00534300 - Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker Phase 1/Phase 2
Terminated NCT00524862 - Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death N/A
Recruiting NCT00181233 - Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
Active, not recruiting NCT04036695 - Arrhythmia in Hemodialysis Patients N/A